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Abstract
Purpose of Review Hypercholesterolemia and statin treatment are nowadays common among people older than 75 years, but
clinical heterogeneity in this increasing age group is wide, and treatment decisions may differ from those in younger patients.
Aim is to discuss the presentation, modifying factors, and treatment decisions of hypercholesterolemia (usually with statins) in
older persons and focusing on primary prevention.
Recent Findings There are no randomized controlled trials in persons older than 80 years at baseline. Randomized controlled trial
findings in younger patients and 75+ subgroups and in observational studies support treatment in secondary prevention of
atherosclerotic cardiovascular disease (ASCVD), but trial evidence in primary prevention is less clear. Available data do not
imply specific harms in older patients, and, therefore, also, judicious primary prevention is possible. However, persons older than
75 years are biologically a very heterogeneous group with frequent frailty, comorbid conditions, and multiple concomitant drugs.
All these, as well as personal preferences, must be taken into account in treatment decisions.
Summary Statin treatment is only one way to prevent ASCVD in older people. Treatment of hypercholesterolemia should be
started far before 75–80 years, and there is no need to discontinue statin treatment due to chronological age alone. After 75 years,
treatment should be started in patients with ASCVD and judiciously in primary prevention. Like all prevention, statin treatment
should be discontinued when palliative treatment is started. Ongoing and planned trials in 70+ individuals will give more
information about primary prevention in older persons.
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Introduction
Patients aged 75–80 years and over are an increasing group of
people in aging societies worldwide and, also, an increasing
target of prevention. Because prevention requires a certain
amount of life expectancy to be relevant, it is important to
realize that the mean life expectancy for an 80-year-old wom-
an is between 7.4 and 10.6 years and for an 80-year-old man
between 6.3 and 8.6 years (http://stats.oecd.org/Index.aspx/
DataSetCode=HEALTH_STAT). It is also important to
consider the overall functioning and quality of life of older
people, and there are several lines of evidence that these have
been improving. For example, a study comparing groups of
people born in 1905 or 1915 (ages 93 and 95 years,
respectively) indicated that people continue to very old age
with better functioning [1]. Consequently, not only curative or
palliative but also preventive efforts are getting more and
more important among oldest patients.
While smoking cessation plays no more a great role among
people aged 75 years and older, important preventive efforts
of cardiovascular disease (CVD) include treatment of hyper-
tension and anticoagulation to prevent stroke in atrial fibrilla-
tion. Also, hypercholesterolemia is common, and accordingly,
use of the inhibitors of 3-hydroxy-3-methylglutaryl coenzyme
A (HMG-CoA) reductase (statins) has greatly increased espe-
cially during the last decade among the oldest age groups. In a
large US survey, the prevalent use was 29, 24, and 14% in the
age ranges of 80–84, 85–89, and over 90 years, respectively
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[2]. On the other hand, older patients often have low adher-
ence and are discontinuing statin treatment, especially in pri-
mary prevention [3, 4].
Paradoxically, several epidemiological studies have
suggested that in old age low cholesterol is associated with
worse prognosis [5], and this has led to concerns and crit-
icism about the relevance of giving statins to older people
despite their high cholesterol in primary prevention. The
question is important, because the decline in atherosclerot-
ic CVD (ASCVD) mortality before 65 years has led to
increased numbers of older patients at risk or with manifest
ASCVD, for which LDL cholesterol is the leading causa-
tive factor [6••]. Moreover, common geriatric conditions,
including dementia and frailty, may have atherosclerotic
origins [7, 8••], and arterial aging [9•] further disposes
older people to vascular disease.
This narrative review is partly based on an earlier review
[10] of the best available evidence up to 2014 of hypercholes-
terolemia and its treatment in people aged 80 years and over.
Focus here is in studies after 2014 and in primary prevention
with statins. For secondary prevention, I can concur with the
American guideline on the treatment of blood cholesterol
[11••], which also includes recommendations for patients
older than 75 years.
General Outline of Hypercholesterolemia
Treatment
There is an established and graded association between
serum cholesterol and ASCVD risk [6], and usually hy-
percholesterolemia is considered to be present when total
cholesterol exceeds 5 mmol/L on the average correspond-
ing to 3 mmol/L for LDL cholesterol. LDL is the primary,
“predisposing” cause of ASCVD, and its lowering with
various treatments, like statins and new proprotein
convertase subtilisin/kexin type 9 (PCSK9) inhibitors,
have been robustly shown to reduce cardiovascular mor-
bidity and mortality (statins), in trials with median age
around 60 years [12••, 13•].
Atherosclerotic process in the arterial wall starts to de-
velop at LDL cholesterol levels over 1.8 mmol/L.
However, the development of clinical ASCVD events,
myocardial infarctions and strokes, in midlife and old age
is also influenced by “precipitating” factors (smoking, hy-
pertension, diabetes) superimposed on LDL cholesterol.
Therefore, total ASCVD risk is used to indicate the need
and mode for hypercholesterolemia treatment [11••].
Although treatment is often started late, it is evident that
the oldest statin users have a long-term “cholesterol bur-
den” in their arteries. This should be remembered when
older statin users and nonusers are compared.
Paradox of Low Cholesterol in Old Age
One of the reasons for low adherence of statin treatment in
older people may be the aforementioned paradox in epidemi-
ological studies suggesting low cholesterol in old age is asso-
ciated with increased mortality risk [5]. However, Mendelian
randomization studies indicate that high LDL cholesterol level
preserves its risk function even in the oldest-old [14].
For the explanation of the paradox, important confounders
affecting both cholesterol level and mortality must be taken
into account. In old age and frailty, low serum cholesterol
may be a marker of changes in cholesterol metabolism [15],
a marker of terminal decline [16], or a marker of subclinical
disease, such as cancer [17, 18]. Inflammation is mediated by
interleukins (IL-6) which increase LDL receptors leading to
lower serum LDL cholesterol levels [19•]. These background
factors are the true reason for worse prognosis (Fig. 1).
Consequently, “exogenous” (therapeutic) cholesterol-
lowering must be differentiated from cholesterol lowering
due to internal, “endogenous” mechanisms. Neither is there
evidence that current treatments would reduce LDL cholesterol
too much, because very low levels (0.5–1.0 mmol/L, even
lower) are sufficient for cellular functions [6, 13•].
Statin Treatment in Older People
When assessing the effects and studies of statins in people
older than 75 years, several aspects should be taken into ac-
count (Table 1).
Starting Before or After 75 Years
There is robust evidence that statin treatment—when started in
midlife—is beneficial for reducing even total mortality in pri-
mary prevention [12••]. It is difficult to comprehend that this
effect would vanish after some arbitrary age threshold, and there
are several studies where ongoing statin treatment is associated
with better prognosis in older people, too [10, 20, 21]. The
ACC/AHAguideline supports continuing statin beyond75years
in persons already taking and tolerating the drug [11••], and an
algorithm has been published to guide treatment [10].
Fig. 1 Explanation to the “cholesterol paradox,” that is, worse prognosis
with lower cholesterol level in observational studies
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It can be claimed that only “deprescribing” studies could
confirm the question about benefits of continuing earlier
started treatment in old age. Some studies have investigated
the effects of discontinuation at the very end of life and show-
ing benefit for quality of life [22]. However, an unblinded
study is open to bias. Given the better prognosis with statin
treatment in epidemiological studies, also ethical questions
should be considered in discontinuation of statin treatment in
old age [23]. There is an ongoing trial in France, Statins In The
Elderly (SITE, NCT02547883), which is recruiting 2430 par-
ticipants aged 75 years and over and treated in primary pre-
vention. Among them, statin treatment will be randomly
discontinued or continued. The participants will be
followed-up every 3 months for a total of 36 months, and
clinical events and economic impact were also registered.
The trial has started in 2016 and expected to close in 2021.
Heterogeneity of Older People
People older than 75 years are biologically very heteroge-
neous, ranging from institutionalized patients with dementia
to robust and strong old individuals. They may have features
(frailty, multimorbidity, polypharmacy, increased vulnerabili-
ty to adverse effects, competing mortality, etc.), which usually
have not been addressed or such patients excluded in random-
ized trials, and this must be taken into account when individ-
ual prevention is considered. Prevention may also be futile, if
started too late—for example, in patients with dementia, late-
stage heart, or kidney failure [24–26]. On the other hand,
when used in persons with low risk, adverse effects of drugs
may exceed benefits.
Age itself is a powerful risk factor due to the accumulation
of cellular damage from aging and risk factor burden.
Moreover, the predictive value of traditional risk factors—
e.g., cholesterol, blood pressure, and obesity—may be re-
versed in old age (see previous texts). Therefore, focusing
primary prevention to those older individuals with most ben-
efit is challenging. Assessment of frailty [27], biomarkers—
such as homocysteine [28]—or more conventional indicators
of ASCVD, for example, coronary calcium score, carotid in-
timamedia thickness, and genetic markers, may offer methods
to better assess risk, but their use is not established.
On the other hand, it is reassuring that in epidemiologic
studies ongoing statin treatment has been beneficial irrespec-
tive of multiprognostic factors [20, 21] and statin efficacy
noted in RCTs is similar in “real-life” and with other drug
treatments [29]. The significance of potential adverse effects
of statins is accentuated in primary prevention, because bene-
fits are smaller (or are achieved later) in people at lower
ASCVD risk. These will be discussed next.
Role of Adverse Effects
Common concerns of statin treatment in older people have
included fears of myalgia and myositis, diabetes, cognitive
disorders, hemorrhagic stroke, fatigue, and loss of energy
leading to less physical activity, worsened quality of life,
and drug interactions in patients with polypharmacy. As most
of these have not been observed in RCTs, this has been ex-
plained by the focus of clinical trials on efficacy endpoints,
and, therefore, less serious adverse effects may not have been
fully recorded. They would nevertheless be important in frail
older people if they lead, for example, to physical inactivity
and functional decline. Frail individuals with comorbidity and
polypharmacy may also be more prone to adverse effects and
drug interactions, and participants with these problems have
been usually excluded from clinical trials. Furthermore, seri-
ous adverse events may also be more frequent in “real life”
conditions than in controlled studies.
The RCT-established and well-known adverse effects of
statins have included effects on liver enzymes, musculoskele-
tal effects, and development of diabetes [12••]. Although sev-
eral other adverse effects have been suspected, there is seldom
consistent evidence of a cause–effect relationship [30, 31].
The muscle-related effects are potentially the most impor-
tant ones for an older patient. These effects range from pains
without serum creatinine kinase (CK) elevations to rhabdomy-
olysis, but the occurrence of life-threatening toxicity is rare.
Milder symptoms, myalgia and cramps, without CK eleva-
tions are common in “real-life” settings, but true cause–
effect relationship is often difficult to establish. In a large
observational study (PRIMO), muscle symptoms were report-
ed by 10.5% [32], which nevertheless would mean a large
number of individuals, because statin use is so common.
Among vulnerable older people, adverse muscle effects
could promote sarcopenia and predispose to frailty, falls, and
morbidity especially in nursing home residents. However,
hard evidence for this is absent in available studies [10], and
statin treatment has no general deteriorating effect on frailty
nor on physical function. At the individual level, it is still
important to observe potential adverse effects like drug inter-
actions, dehydration, and comorbidity in a frail patient.
Elevations of hepatic transaminases usually resolve spon-
taneously, after dose reduction or discontinuation of the drug.
Table 1 Points to consider about statin treatment in older people
- Is statin treatment ongoing or started after 75 years of age?
- What are the individual characteristics: robust vs frail and multimorbid;
living in the community vs nursing home residents (who include an
increasing proportion of individuals with advanced dementia); short vs
long life expectancy.
- Role of adverse effects potentially specific for older people.
- What is the difference between primary vs secondary prevention in
patients over 75 years of age?
- What about treatment after 80–85 years?
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Progression to serious liver damage is extremely rare, and
routine liver enzyme testing is not needed.
Statin treatment is associated with a slightly increased risk
of diabetes, but, in older people, the clinical significance is
unclear, and statin treatment also benefits patients with
diabetes [12••]. At present, there is no firm evidence that statin
treatment would have either positive or negative effect on
cognition [12••, 30, 31], and very low cholesterol is not asso-
ciated with cognitive impairment [33]. Given the established
effect of preventing ischemic stroke [12••], a risk factor for
Table 2 Recent observational studies and randomized controlled trials of statins in older people without atherosclerotic cardiovascular disease
(ASCVD)
Source No. of participants with
details of age (year)
Mean/median
follow-up (year)
Patients Findings in statin users vs nonusers
(or less intensive treatment)
Observational studies
Orkaby et al. [38] 1130 statin users were
matched to
nonusers > 70 years
Total n = 7213
7 Primary prevention All-cause mortality: HR 0.82, 95% CI 0.69–0.98
CVD events: HR 0.86, 95% CI 0.70–1.06
Stroke: HR 0.70, 95% CI 0.45–1.09
In subgroup analyses, results were similar in age
groups at baseline (70–76 or > 76 years) or
according to functional status.
Ramos et al. [39] 7502 new statin users were
matched to nonusers,
> 75 years
Total n = 46,864
5.6 Primary prevention 75–84 year olds without diabetes:
ASCVD: HR 0.94, 95% CI 0.86–1.04
All-cause mortality: HR 0.98, 95% CI 0.91–1.05
85 and older without diabetes
ASCVD: HR 0.93, 0.82–1.06
All-cause mortality: HR 0.97, 95% CI 0.90–1.05
75–84 year olds with diabetes
ASCVD: HR 0.76, 95% CI 0.65–0.89
All-cause mortality: HR 0.84, 95% CI 0.75–0.94
85 and older with diabetes
ASCVD: HR 0.82, 95% CI 0.53–1.26
All-cause mortality: HR 1.05, 95% CI 0.86–1.28
Bezin et al. [40] New statin users matched
to nonusers, > 75 years.
Total n = 7284
4.7 Primary prevention HR 0.93 (95% CI 0.89–0.96) in people with
modifiable risk factors (diabetes or
cardiovascular medications). HR 1.01 (95%
CI 0.86–1.18) in people without modifiable
risk factors
Jun et al. [41] 11,017 > 75 years Nested case–control Primary prevention Composite outcome: adjusted OR [AOR] 0.77;
95% CI 0.71–0.84
Stroke: AOR 0.74; 95% CI 0.61–0.89
All-cause death: AOR 0.73; 95% CI 0.66–0.81
Kim et al.
(SCOPE-75) [42]
639 statin users,
639 statin never users,
> 75 years
5.2 Primary prevention
(but with ASCVD
risk factors)
Major adverse cardiovascular and
cerebrovascular events: HR 0.59,
95% CI 0.41–0.85.
All-cause death: HR 0.56, 95% CI 0.34–0.93.
Randomized controlled trials
JUPITER 5695 > 70 years 2.2 Primary prevention Combined cardiovascular end point:
HR 0.61; 95% CI 0.43–0.86; P = 0.004
All-cause mortality: HR 0.80; 95% CI 0.62–1.0;
P = 0.09
HOPE-3 3086 > 70 years 5.0 Primary prevention Combined cardiovascular end point:
HR 0.83; 95% CI 0.64–1.07; P = 0.16
All-cause mortality: HR 0.91;
95% CI 0.73–1.13; P = 0.38
Meta-analysis of
JUPITER and
HOPE-3 [43]
8781 > 70 years Composite end point of nonfatal myocardial
infarction, nonfatal stroke, or cardiovascular
death: HR 0.74, 95% CI 0.61–0.91
Meta-analysis of
statin trials in older
people [37••]
14,483 > 75 years 4.9 Primary and secondary
prevention
Major vascular events:
Primary prevention HR 0.92, 95% CI 0.73–1.16
Secondary prevention: HR 0.85,
95% CI 0.73–0.98
   28 Page 4 of 7 Curr Atheroscler Rep           (2019) 21:28 
cognitive decline, statin treatment could be rather anticipated
to be beneficial through that mechanism. Slightly increased
risk of hemorrhagic stroke has been noted in patients with
prior stroke [12••, 31], but lower risk was recently observed
in a survey of a large population without previous stroke [34].
Finally, although RCTs of statins have been negative in
advanced heart failure, late-stage renal disease, or dementia,
neither have specific harms been detected in these most vul-
nerable patient groups. In a large real-life database, statins
appeared to be similarly tolerated in older (> 75 years) and
younger adults in primary prevention [35]. In accordance,
health-related quality of life was similar among home-living
octogenarian statin users as compared to nonusers [36].
Statin Treatment Started in Old Age in Primary
Prevention
Meta-analysis of statin trials has revealed that each 1 mmol/L
reduction in LDL cholesterol decreases the yearly rate of major
ASCVD events by one fifth and total mortality by 10% [12••].
The relative reduction of ASCVD has been independent of
baseline LDL cholesterol level and of various subgroups.
With relative risk of ASCVD being constant and absolute risk
higher in older people, statin treatment should lead to benefits
also in people aged 75 and older. This is clearly the case for
secondary prevention according to a meta-analysis of random-
ized statin trials [37••]. The meta-analysis included 14,483 par-
ticipants older than 75 years, and statin treatment was associat-
ed with a 15% reduced rate of major vascular events (HR 0.85,
95% CI 0.73–0.98) among those with existing ASCVD.
In primary prevention, direct evidence of benefit in age
groups 75 years and over has been less clear in RCTs [37••].
Observational studies up to 2014 have suggested mixed ben-
efit, and recent observational statin studies (mostly > 75 years,
some starting from 70 years) and new analyses of older RCTs
in primary prevention are shown in Table 2 [38–43]. Overall,
the results are not unequivocal but seem to suggest benefits of
starting statin in patients older than 75 years at increased risk
of ASCVD, such as diabetics.
A clinical trial, STAtin Therapy for Reducing Events in the
Elderly (STAREE, NCT02099123), is currently ongoing and
enrolling 18,000 participants for a randomized and placebo-
controlled trial to determine whether atorvastatin (40 mg dai-
ly) will extend the length of a disability-free life (survival
outside permanent residential care) among healthy partici-
pants aged 70 years and older. The trial has started in 2015
and is expected to close in 2023. Primary outcome measures
of STAREE are either (1) death or development of dementia
(measured by cognitive function tests) or development of dis-
ability (measured by the KATZ ADL test) or (2) a major fatal
or non-fatal CVD event. Numerous secondary outcomes, such
as quality of life, cognitive decline, frailty, and cost-effective-
ness, will also be analyzed.
Oldest-Old
There are no randomized studies about starting statin specifi-
cally after 80 or 85 years, and the oldest age groups (including
only modest number of individuals) are not separated in trials.
According to expert groups of the American National Institutes
of Aging (NIA) [44], prospective, traditional, placebo-con-
trolled, randomized clinical trials, and pragmatic trials would
be suitable options to address gaps in knowledge of oldest
patients. Accordingly, the experts urge to include better repre-
sentation of very old adults, women, underrepresented minori-
ties, and individuals with various health status, cognitive, so-
cioeconomic, and educational backgrounds in future trials.
However, it may be challenging to recruit oldest patients for a
placebo-controlled trial and it is feared that a potentially nega-
tive result (like lack of effect of statins in end-stage disease)
would be wrongly applied to those older patients, whose treat-
ment has been started earlier in life, simply because of age [45].
Conclusions
We have earlier constructed a treatment algorithm for statin
treatment in people older than 80 years taking into account
whether the treatment is ongoing or considered de novo [10].
Evidence accumulated after 2014 does not give reason to
change the general principles in older patients. Statin treatment
is generally safe and well-tolerated also in older patients, and
ongoing treatment should be continued after 75 years. Starting
treatment in primary prevention in older age is indicated, if the
patient is considered to be at increased risk for ASCVD.
However, individual assessment and shared decision-making
(provided the patient has truthful information about statins!)
are important, and it is also important to secure adherence.
Ongoing trials will give further information in the older patient
groups and will be available in the early 2020s.
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